Harmony Biosciences Holdings, Inc.(HRMY)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Harmony Biosciences Holdings, Inc. (HRMY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HRMY at 71.4/100 on a 32-signal composite quality model, placing it at rank #185 of 2,960 stocks — the top 10% of the AI-ranked universe. HRMY scores in the top quartile across balance sheet strength (92.6), free cash flow (89.4), revenue growth (83.9). Areas of concern include institutional flow (10.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Harmony Biosciences Holdings, Inc. reports quarterly revenue of $261.3M, net income of $75.4M. Top institutional holders of HRMY by reported 13-F value include BlackRock, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. HRMY trades on the Nasdaq exchange and files with the SEC under CIK 1802665. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HRMY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Harmony Biosciences Holdings, Inc. directly from SEC EDGAR.
AI Quality Score
71.4/100
AI Rank
#185
Revenue
$261.3M
Net Income
$75.4M
HRMY key financials by period
Harmony Biosciences Holdings, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$868.5M
$158.7M
24.0%
FY 2024
10-K
$714.7M
$145.5M
26.7%
FY 2023
10-K
$582.0M
$128.9M
33.0%
FY 2022
10-K
$437.9M
$181.5M
27.5%
FY 2021
10-K
$305.4M
$34.6M
28.7%
FY 2020
10-K
$159.7M
$-36.9M
10.6%
Institutions holding HRMY
Institutional investors reporting a position in Harmony Biosciences Holdings, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net product revenue from sole product WAKIX rose 30.3% YoY to $261.3M on 26.5% unit growth plus a 7% price increase, lifting net income to $75.4M from $39.8M.
Biggest Revenue Drivers
Rare neurological diseases (WAKIX net product revenue)$261.3M+30.3% YoY
Sole reportable segment; all revenue derived from sales of WAKIX in the United States
Biggest Revenue Drivers
Total revenue: $261.3M+30.3% YoY
Rare neurological diseases (WAKIX net product revenue)$261.3M+30.3% YoY
Sole reportable segment; all revenue derived from sales of WAKIX in the United States
Within Rare neurological diseases (WAKIX net product revenue)
Units shipped+26.5% YoY
Average patients on WAKIX was approximately 8,950 for the three months ended June 30, 2026
Price+7%
January 2026 price increase, partially offset by higher rebates of approximately 4.0%
Largest Expense Items
Cost of product sold$63.2M+65.6% YoY
Higher royalties on increased WAKIX net revenue, plus new royalties under the Novitium License Agreement
Research and development$46.6M-7.1% YoY
Prior-year $15.0M CiRC IPR&D charge and ZYN002 phase-out, offset by $16.4M more spend on BP-205, EPX-100, Pitolisant GR/HD
Sales and marketing$34.1M+13.5% YoY
$2.0M more patient engagement and marketing and $1.6M higher personnel costs from sales force expansion
General and administrative$28.1M-17.3% YoY
$5.1M lower legal and professional fees after prior-year ANDA settlements and $2.4M less stock compensation
Margins: Cost of product sold rose to 24.2% of net product revenue from 19.0% a year ago, driven by new Novitium royalties; gross profit was $198.1M and operating income $89.3M.
Watch Items from the Filing
Three specialty pharmacies were 100% of gross product revenue for the six months: CVS Caremark 38%, Accredo 37%, Pantherx 25%; same three are 100% of receivables.
Generic settlements license WAKIX generics from July 2030 (Hikma March 2030) if pediatric exclusivity is granted; consolidated ANDA bench trial concluded February 19, 2026, oral arguments October 22, 2026.
Single commercialized product WAKIX, dependent on two API suppliers; supply covers demand into Q4 2028 with API for at least 24 months beyond.
$962.5M cash and investments against $155.0M debt; a nonfinancial covenant event of default dating to July 2025 was waived May 4, 2026.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
